I-Flow appoints Smith and Nephew for PainBuster in US:
This article was originally published in Clinica
Smith & Nephew will become exclusive distributor in the US and Canada for PainBuster, I-Flow's disposable orthopaedic pain management system. The company claims the product has advantages over general post-operative pain reduction regimes, in that it uses non-narcotic bupivacaine infused directly into the wound site. PainBuster, which will be sold under S&N's DonJoy brand, is said to reduce post-operative costs and allow for earlier patient mobility. The five-year deal calls for S&N to make a purchase commitment of $2 million from Lake Forest, California-based I-Flow.
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.